Literature DB >> 17763598

Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.

Josephine A Taverna1, Adam Lerner, Jag Bhawan, Marie-France Demierre.   

Abstract

Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions. The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17763598

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN： 1545-9616            Impact factor:   2.114


  8 in total

1.  Rituximab for autoimmune blistering diseases: recent studies, new insights.

Authors:  L Lunardon; A S Payne
Journal:  G Ital Dermatol Venereol       Date:  2012-06       Impact factor: 2.011

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 3.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

4.  Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

5.  Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study.

Authors:  Caiyun You; Neerav Lamba; Andres F Lasave; Lina Ma; Mikhail Hernandez Diaz; C Stephen Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-03       Impact factor: 3.535

6.  Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom.

Authors:  G P Williams; C Radford; P Nightingale; J K G Dart; S Rauz
Journal:  Eye (Lond)       Date:  2011-07-29       Impact factor: 3.775

7.  Rituximab in severe skin diseases: target, disease, and dose.

Authors:  Daniel D Bennett; Maro Ohanian; Christian T Cable
Journal:  Clin Pharmacol       Date:  2010-07-07

Review 8.  Off-Label Uses of Rituximab in Dermatology.

Authors:  Connor Cole; Kyle T Amber
Journal:  Curr Dermatol Rep       Date:  2022-10-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.